MX2019003945A - Formas cristalinas y salinas de compuestos agonistas de ppar. - Google Patents
Formas cristalinas y salinas de compuestos agonistas de ppar.Info
- Publication number
- MX2019003945A MX2019003945A MX2019003945A MX2019003945A MX2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A
- Authority
- MX
- Mexico
- Prior art keywords
- salt forms
- crystalline
- agonist compounds
- ppar agonist
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta divulgacion se relaciona con formas salinas de compuestos que tienen capacidad para activar PPARd para su uso en el desarrollo de farmacos y productos farmacologicos, y composiciones y metodos relacionados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003945A true MX2019003945A (es) | 2019-09-18 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003945A MX2019003945A (es) | 2016-10-05 | 2017-10-05 | Formas cristalinas y salinas de compuestos agonistas de ppar. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (es) |
| EP (1) | EP3523283B1 (es) |
| JP (1) | JP7017563B2 (es) |
| KR (1) | KR20190057129A (es) |
| CN (1) | CN109843857B (es) |
| AU (1) | AU2017340763B2 (es) |
| BR (1) | BR112019006030A2 (es) |
| CA (1) | CA3036587A1 (es) |
| CO (1) | CO2019003162A2 (es) |
| CY (1) | CY1124655T1 (es) |
| DK (1) | DK3523283T3 (es) |
| ES (1) | ES2887008T3 (es) |
| HR (1) | HRP20211341T1 (es) |
| HU (1) | HUE055678T2 (es) |
| IL (1) | IL265730B (es) |
| JO (1) | JOP20190039B1 (es) |
| LT (1) | LT3523283T (es) |
| MA (1) | MA46460A (es) |
| MX (1) | MX2019003945A (es) |
| MY (1) | MY202008A (es) |
| PH (1) | PH12019500727A1 (es) |
| PL (1) | PL3523283T3 (es) |
| PT (1) | PT3523283T (es) |
| RS (1) | RS62245B1 (es) |
| RU (1) | RU2759724C2 (es) |
| SG (1) | SG11201901995TA (es) |
| SI (1) | SI3523283T1 (es) |
| TW (1) | TWI769182B (es) |
| UA (1) | UA124770C2 (es) |
| WO (1) | WO2018067860A1 (es) |
| ZA (1) | ZA201901744B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| EP3795566B1 (en) * | 2015-10-07 | 2023-04-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| TWI769182B (zh) | 2016-10-05 | 2022-07-01 | 美商米突倍基公司 | 過氧化物酶體增生劑活化之受體（ppar）促效劑化合物之結晶及鹽形式 |
| AU2018348174A1 (en) | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| SG11202103984WA (en) * | 2018-10-23 | 2021-05-28 | Japan Science & Tech Agency | PPARd activator |
| CA3221429A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585733A1 (en) | 2003-01-06 | 2005-10-19 | Eli Lilly And Company | Heterocyclic ppar modulators |
| EP1671633A1 (en) * | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| AU2006210503B2 (en) * | 2005-02-03 | 2009-09-03 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EP3795566B1 (en) | 2015-10-07 | 2023-04-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US11358954B2 (en) * | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| TWI769182B (zh) | 2016-10-05 | 2022-07-01 | 美商米突倍基公司 | 過氧化物酶體增生劑活化之受體（ppar）促效劑化合物之結晶及鹽形式 |
| US20210283116A1 (en) | 2016-10-05 | 2021-09-16 | Mitobridge, Inc. | Methods of treating acute kidney injury |
-
2017
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en active Application Filing
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 BR BR112019006030A patent/BR112019006030A2/pt active Search and Examination
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500727A1 (en) | Crystalline and salt forms of ppar agonist compounds | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| EP3250048A4 (en) | Oligosaccharide compositions for use animal feed and methods of producing thereof | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2016015743A (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa. | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
| ZA202003663B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| MX2017001379A (es) | Producto antiseptico, proceso para prepararlo y su uso. | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| TN2016000535A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases. | |
| MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
| MX2017003697A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y uso como moduladores selectivos de glucorticoides (sgrm). | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| CL2015002712A1 (es) | Cristales de laquinimod sódico y proceso para la preparación de ellos | |
| EP3694629A4 (en) | COMPOSITION OF UREA FOR USE IN THE PRODUCTION OF Lye | |
| PL3398946T3 (pl) | Sól pochodnej morfolinowej i jej postać krystaliczna, jak również sposób jej wytwarzania, kompozycja farmaceutyczna i jej zastosowanie | |
| MX2015014657A (es) | Nuevos agentes antibacterianos de fenicol. | |
| PH12016502466A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases | |
| IN2013MU02610A (es) |